规格: | 98% |
分子量: | 675.26 |
包装 | 价格(元) |
1mg | 电议 |
5mg | 电议 |
10mg | 电议 |
25mg | 电议 |
50mg | 电议 |
Background:
Vazegepant (BHV-3500) hydrochloride is a highly affinity CGRP receptor antagonist (hCGRP Ki= 0.023 nM). Vazegepant hydrochloride is the first intranasal gepant for migraine. Vazegepant hydrochloride may be helpful in effective management of COVID-19 associated pulmonary inflammation[1][2][3].
[1]. Moreno-Ajona D, et al. Gepants, calcitonin-gene-related peptide receptor antagonists: what could be their role in migraine treatment•. Curr Opin Neurol. 2020;33(3):309-315.
[2]. Mehta PP, et al. Novel and Evolving Therapies for COVID-19 Related Pulmonary Complications. Am J Med Sci. 2021;361(5):557-566.
[3]. Moreno-Ajona D, PÉrez-RodrÍguez A, Goadsby PJ. Gepants, calcitonin-gene-related peptide receptor antagonists: what could be their role in migraine treatment•. Curr Opin Neurol. 2020;33(3):309-315.